IFNA1 and systemic lupus erythematosus: •   SynBioSe study (NCT02284984) showed that combination treatment with rituximab and belimumab reduced NETformation in SLE patients•   Phase I study will investigate the safety and tolerability of tofacitinib in SLE patients•   A study in Chinese patients (ChiCTR-TRC-12002419) showed that metformin added to conventional treatment for 12months in SLE patients with mild-to-moderate disease decreased SLEDAI score by over 50%•   Metformin reduced NET formation in neutrophils stimulated with PMA and decreased IFN-α secretion in plasmacytoiddendritic cells